Navigation Links
Cornerstone Therapeutics Announces Closing of Chiesi Transaction
Date:7/30/2009

ing our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient enrollment, data collection or data analysis; the results of preclinical studies and clinical trials with respect to our products under development and whether such results will be indicative of results obtained in later clinical trials; our ability to satisfy FDA and other regulatory requirements; our ability to obtain, maintain and enforce patent and other intellectual property protection for our products and product candidates; and the other factors described in Item 1A (Risk Factors) of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the SEC) on May 7, 2009 and other filings that we make with the SEC. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise. Our forward-looking statements do not reflect the potential impact of any acquisitions, mergers, dispositions, business development transactions, joint ventures or investments that we may make or enter into, except that in particular circumstances as specifically indicated we may address the potential impact of our transaction with Chiesi. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this release.


'/>"/>
SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
2. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
3. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
4. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
5. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
6. Amicus Therapeutics Announces Second Quarter 2009 Financial Results Release Date
7. PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2
8. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
9. United Therapeutics Corporation to Announce Second Quarter 2009 Financial Results Before Market Open on Friday, July 31, 2009
10. Cell Therapeutics, Inc. Announces Exercise of Overallotment
11. Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
(Date:12/24/2014)... December 23, 2014 GMO corn cases filed ... are in the process of being consolidated in a Kansas ... Re: Syngenta AG MIR 162 Corn Litigation, MDL No. 2591 ... , Management of the Syngenta GMO corn multidistrict litigation (MDL) ...
(Date:12/24/2014)... 23, 2014 On Friday, December 19, ... Omnibus and Continuing Resolution Appropriations Act of 2015, which ... to receive funding through the Congressionally Directed Medical Research ... The Hydrocephalus Association (HA), working in conjunction with its ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. ... Society for Reproductive Medicine (ASRM), a leading professional organization committed ... his new role as treasurer, Dr. Hill also fills a ... in furthering the mission of ASRM. , Dr. Hill ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... Xybion Medical ... its Research and Development facility in Fair Lawn, New Jersey. , ... Cedar Knolls, NJ (PRWEB) August 3, 2009 -- Xybion ... of Pristima™ the premier preclinical solution on the market, is pleased to announce that SK ...
... , , , ... Inc. (Nasdaq: GHDX ) today reported financial results and business progress ... revenue increased to $36.6 million in the second quarter of 2009 compared with ... Onco type DX(R) breast cancer test was $35.2 million in the second ...
... 4 /PRNewswire-Asia/ -- Shanghai ChemPartner Co., Ltd.,(ChemPartner) a wholly ... moved its drug discovery collaboration with ELARA,Pharmaceuticals to a ... the areas of DMPK, pharmacology and toxicology for ELARA,s ... from both sides will,work closely together to design and ...
Cached Biology Technology:SK Life Sciences has Licensed Pristima 2Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 2Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 3Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 4Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 5Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 6Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 7Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 8Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 9Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level 2
(Date:1/22/2015)... N.C. , Jan. 22, 2015 Infinisource has launched ... of the G2 model. The G2 sets a higher standard ... iSolved human capital management solution. With plug-and-play installation, touch screen ... time clock provides a robust time collection solution for the ...
(Date:12/22/2014)... Holiday Season may be the brightest ever for the ... long anticipated floodgates for consumer biometrics may finally be ... tablets, and wearable mobile devices that incorporate biometrics will ... nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ...
Breaking Biology News(10 mins):Infinisource's NXG series sets new time clock standard 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... LAFAYETTE, Ind. - Proper and timely burning of some Eastern ... a wide range of species, a Purdue University report shows. ... nutrient from deep in the soil and depositing it on ... an important source of nutrition for a variety of species ...
... been a hot savanna region for at least the past ... hominids evolved in this areasays a team of researchers led ... findings may shed light on the evolutionary pressures that led ... develop a more slender physique, and sweat more copiously than ...
... , New Rochelle, NY, June 8, 2010The growing use ... may help individuals with diabetes optimize blood glucose control ... with diabetes, as described in a Special Supplement to ... published by Mary Ann Liebert, Inc. (http://www.liebertpub.com). The issue ...
Cached Biology News:Fire may be key to reviving dogwood trees in Eastern forests 2East-African human ancestors lived in hot environments, says Caltech-led team 2East-African human ancestors lived in hot environments, says Caltech-led team 3Importance of insulin delivery devices for diabetes management 2
Request Info...
... Hematopoietic stem cells (HSC) are well-characterized tissue-specific ... and are responsible for the life-long maintenance ... cells that reside in adult bone marrow ... can also be found in cord blood, ...
... polyclonal to Atrophin 1 ( Abpromise ... Antigen: Synthetic peptide conjugated to KLH ... C-terminus of Human Atrophin 1.(Note: the amino ... ab32861 .) Entrez GeneID: ...
NNT-1/BSF-3 (N-14)...
Biology Products: